The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Large Will The GLP-1 Receptor Agonist Market Be By 2030 Compared To Its 2026 Market Size?
The glp-1 receptor agonist market has experienced significant expansion in its size over recent years. It is projected to expand from $14.09 billion in 2025 to reach $14.83 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 5.3%. Historically, this growth has been driven by several factors, including the increasing prevalence of type 2 diabetes, greater awareness of glycemic control therapies, the robust clinical effectiveness shown against traditional antidiabetics, physician preference for incretin-based treatments, and favorable reimbursement policies in developed markets.
The glp-1 receptor agonist market is anticipated to experience robust expansion in the coming years, with its size projected to reach $18.32 billion by 2030, driven by a compound annual growth rate (CAGR) of 5.4%. This growth during the forecast period is attributed to factors such as an increasing global obesity population, broadening approvals for cardiovascular risk reduction, advancements in oral and combination therapies, greater market penetration in emerging regions, and a rising patient preference for weight loss benefits. Noteworthy trends expected over this period include the expansion of glp-1 therapies beyond diabetes, an escalating demand for long-acting and once-weekly formulations, the proliferation of oral glp-1 receptor agonists, an intensified focus on weight management indications, and the establishment of strategic partnerships and licensing agreements.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9631&type=smp
Which Key Factors Are Driving The GLP-1 Receptor Agonist Market Growth?
An increasing occurrence of diabetes is projected to drive the GLP-1 receptor agonist market in the future. This chronic disease arises when the pancreas either fails to produce enough insulin or the body struggles to effectively use the insulin it generates. Elevated blood sugar is a characteristic sign of the metabolic condition known as diabetes mellitus. In diabetes treatment, GLP-1 receptor agonists prompt the body to create additional insulin, thereby assisting in the reduction of blood sugar levels, consequently, the increasing incidence of diabetes will boost market expansion. As an illustration, data from March 2024, provided by the Office for Health Improvement and Disparities, a UK government body, indicated that from March 2022 to March 2023, there was a 22% rise in the proportion of people with type 1 diabetes receiving all eight suggested care processes, and a 21% rise for type 2 diabetes, while the proportion reaching target HbA1c levels climbed to 37.9%. Thus, the growing occurrence of diabetes is fueling the GLP-1 receptor agonist market.
What Are The Different Segment Types In The GLP-1 Receptor Agonist Market Segment Breakdown?
The glp-1 receptor agonist market covered in this report is segmented –
1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs
2) By Route Of Administration: Parenteral, Oral
3) By End Users: Hospitals, Surgical Clinics, Other Users
What Trends Are Influencing The Evolution Of The GLP-1 Receptor Agonist Market?
Companies operating in the GLP-1 receptor agonist market are focusing on creating sustained-release GLP-1 receptor agonists to achieve a competitive advantage. Sustained-release GLP-1 receptor agonists (GLP-1RAs) represent a category of medication that gradually releases GLP-1RA into the bloodstream, thereby facilitating extended effects and fewer injections compared to conventional GLP-1RAs. As an example, in April 2023, Mitsubishi Tanabe Pharma Corporation, a Japan-based pharmaceuticals company, introduced Mounjaro 2.5 mg or 5 mg Ateos. This is the world’s first sustained-release GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes that activates both the GLP-1 and GIP receptors. The GLP-1 receptor plays a role in managing blood sugar levels, whereas the GIP receptor contributes to stimulating insulin secretion and decreasing appetite.
Who Are The Well-Known Companies In The GLP-1 Receptor Agonist Market?
Major companies operating in the glp-1 receptor agonist market are Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Merck & Co. Inc., Novartis AG.
Get The Full GLP-1 Receptor Agonist Market Report:
https://www.thebusinessresearchcompany.com/report/glp-1-receptor-agonist-global-market-report
Which Region Is The Leading Market For The GLP-1 Receptor Agonist Market?
North America was the largest region in the GLP-1 receptor agonist market in 2025. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the glp-1 receptor agonist market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized GLP-1 Receptor Agonist Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/glp-1-receptor-agonist-global-market-report
Browse Through More Reports Similar to the Global GLP-1 Receptor Agonist Market 2026, By The Business Research Company
Glp 1 Receptor Agonist Market Report 2026
https://www.thebusinessresearchcompany.com/report/glp-1-receptor-agonist-global-market-report
G Protein Coupled Receptors Market Report 2026
https://www.thebusinessresearchcompany.com/report/g-protein-coupled-receptors-global-market-report
Glucagon Like Peptide 1 Market Report 2026
https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-1-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model